Emitents | Olainfarm, AS (213800WCG52W62ENOP27) |
Veids | Citi |
Valoda | EN |
Statuss | Publicēts |
Versija | |
Datums | 2015-01-13 11:28:03 |
Versijas komentārs | |
Teksts |
Olaine
„Olainfarm” Invests 9.6
Million Euros in New Final Dosage Form Production Unit
Today with participation of
President Andris Berzins of Latvia, the new final dosage form
production unit of AS “Olainfarm” was opened. The unit includes
final dosage form site for nitrofuranes, small batch production
unit and final dosage development laboratory. The project has
been implemented with a support from European Regional Development
Fund.
„”Olainfarm” has always been the most outstanding locomotive of
Latvian chemical industry, which today, with opening of the
capacities is doubling our economic capabilities. Because of
skilful management and introduction of new technologies, the
company has been able to find markets in new and distant
countries,” says President Andris Berzins of
Latvia.
The new production unit has been built through reconstruction of
previously underused building. Its total space is 2112 square
metres. The building has two floors and is connected to the
main final dosage form production unit. On the ground floor there
is a small batch production unit and final dosage development
laboratory, but on the second floor the nitrofurane final dosage
production unit and in-process quality control laboratories are
located.
„New final
dosage form production unit of ”Olainfarm” is a high added value
investment project, that will help company to strengthen its
competitiveness in growing world market of nitrofuranes and will
significantly improve company’s ability to develop new products.
We have a long term experience in production of nitrofuranes,
we are the only producer of them in Latvia and the Baltic States
and the only ones in former Soviet Union who produce active
pharmaceutical ingredients of nitrofuranes. Nitrofuranes make up
more than 20% of sales of „Olainfarm” and during the last five
years sales of nitrofuranes have tripled,” adds Chairman of the
Board of AS „Olainfarm” Mr. Valerijs
Maligins.
Antibacterial nitrofurane derivatives, namely Furamag, Furagin,
Furadonin and Furasol will be produced in the modernized facility,
and after the completion of development process they will be joined
by the new nitrofurane product. New equipment will significantly
improve the efficiency of production processes, making them highly
technological, and at the same time reduce energy consumption.
Small batch final dosage form production unit of AS „Olainfarm”
will produce smaller batches of finished products and will be used
for technology scale-up. Small scale technologies will also allow
optimisation of the use of more productive equipment. Final dosage
form development laboratory has also been moved to the new
building, where it will continue working on new forms of existing
products and on development of brand new
products.
New final dosage production unit of AS „Olainfarm” is the biggest
financial investment in development of pharmaceutical production in
the Baltics in 2014. Total costs of the project are 9.6
million euro, of which 2.5 million euro is funded by European
Regional Development Fund. Of the total project
costs 4.1 million euro were invested in construction works, 4.8 in
production equipment and 0.6 in analytical equipment.
New final dosage form production unit was constructed within the
project „High Added Value Investments into Production of
Nitrofuranes”, on which the contract No.L-APV-12-0039 was signed
between AS „Olainfarm” Latvian Investment and Development Agency on
August 15, 2012.
JSC
Olainfarm is one of the biggest pharmaceutical companies in Latvia
with more than 40 years of experience in production of medication
and chemical and pharmaceutical products. A basic principle of
company's operations is to produce reliable and effective top
quality products for Latvia and the rest of the world. Products
made by the Group are being exported to more than 35 countries of
the world, including the Baltics, Russia, other CIS, Europe, Asia,
North America and Australia
Information
prepared by:
|
Pielikumi |
|